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Abstract
BACKGROUND—Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a
highly selective TRK inhibitor, in adults and children who had tumors with these fusions.
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METHODS—We enrolled patients with consecutively and prospectively identified TRK fusion–
positive cancers, detected by molecular profiling as routinely performed at each site, into one of
three protocols: a phase 1 study involving adults, a phase 1–2 study involving children, or a phase
2 study involving adolescents and adults. The primary end point for the combined analysis was the
overall response rate according to independent review. Secondary end points included duration of
response, progression-free survival, and safety.
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RESULTS—A total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and
treated. Patients had 17 unique TRK fusion–positive tumor types. The overall response rate was
75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI,
67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and
55% of the patients remained progression-free. The median duration of response and progressionfree survival had not been reached. At a median follow-up of 9.4 months, 86% of the patients with
a response (38 of 44 patients) were continuing treatment or had undergone surgery that was
intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of
grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more
than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse events.
CONCLUSIONS—Larotrectinib had marked and durable antitumor activity in patients with TRK
fusion–positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo
Oncology and others; ClinicalTrials.gov numbers, NCT02122913, NCT02637687, and
NCT02576431.)

Address reprint requests to Dr. Hyman at Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, or at
hymand@mskcc.org.
Drs. Drilon and Laetsch, and Drs. Hong and Hyman, contributed equally to this article.
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The neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3 encode the
tropomyosin receptor kinase (TRK) proteins TRKA, TRKB, and TRKC, respectively. After
embryogenesis, TRK expression is limited primarily to the nervous system, where these
kinases help regulate pain, proprioception, appetite, and memory.1 Recurrent chromosomal
fusion events involving the carboxy-terminal kinase domain of TRK and various upstream
amino-terminal partners have been identified across diverse cancers that occur in children
and adults. TRK fusions lead to overexpression of the chimeric protein, resulting in
constitutively active, ligand-independent downstream signaling. Biologic models and early
clinical evidence suggest that these fusions lead to oncogene addiction regardless of tissue of
origin and, in aggregate, may be implicated in up to 1% of all solid tumors.2–7
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We evaluated the efficacy of larotrectinib (Table S1 in the Supplementary Appendix,
available with the full text of this article at NEJM.org), a potent and highly selective smallmolecule inhibitor of all three TRK proteins, in a development program that encompassed
patients of any age and with any tumor type (an “age- and tumor-agnostic” therapy). The
program involved three clinical studies: a phase 1 study involving adults, a phase 1–2 study
involving children, and a phase 2 “basket” study involving adolescents and adults. Here we
report an integrated safety and efficacy analysis of the first 55 consecutively enrolled
patients (a sample size that was established with input from global regulators and that was
designed to rule out a lower estimate of 30% for the overall response rate) with
prospectively identified TRK fusion–positive cancers treated across these studies.

METHODS
PATIENTS
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Specific eligibility criteria varied according to study protocol (all three protocols and the
statistical analysis plan are available at NEJM.org). In general, eligible patients had a locally
advanced or metastatic solid tumor, had received standard therapy previously (if available),
had an Eastern Cooperative Oncology Group performance-status score of 0 to 3 (on a scale
from 0 to 5, with higher scores indicating greater disability), and had adequate major organ
function. An early amendment to the phase 2 study involving adolescents and adults
prohibited previous treatment with kinase inhibitors with anti-TRK activity, although one
such patient was enrolled before this amendment.
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All three protocols were approved by the institutional review board or independent ethics
committee at each site, and all the protocols complied with the International Ethical
Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice
guidelines, the Declaration of Helsinki, and local laws. All the patients, or guardians for
patients younger than 18 years of age, provided written informed consent.
STUDY DESIGN AND TREATMENT
All the patients who enrolled in the phase 1 studies involving adults and children were
treated during the dose-escalation portion of those studies. At the time that the 55th patient
with a TRK fusion–positive cancer was enrolled across the program, the phase 2 portion of
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the phase 1–2 study involving children had not yet started; thus, no patient from that phase 2
study is included in the current report.
The phase 2 study involving adolescents and adults used the recommended dose of 100 mg
of larotrectinib twice daily, administered orally continuously. Although a maximally
tolerated dose of larotrectinib was not defined, a dose of 100 mg twice daily was selected for
adults and children who had a body-surface area of at least 1 m2. For children who had a
body-surface area of less than 1 m2, a twice-daily dose of 100 mg per square meter was
selected. A liquid formulation was available for patients who were unable to swallow
capsules. The drug was administered continuously until disease progression, withdrawal of
the patient from the study, or the occurrence of an unacceptable level of adverse events.

Author Manuscript

The presence of a TRK fusion before enrollment was mandated in the phase 2 basket study
but was not required in the phase 1 studies that involved adults and children, although
patients with prospectively identified TRK fusions in the phase 1 studies were included in
this integrated efficacy analysis. TRK fusions were identified by next-generation
sequencing, according to the procedures and analytic pipelines established by each
laboratory, or by fluorescence in situ hybridization. All the testing was performed in a
Clinical Laboratory Improvement Amendments–certified (or equivalent) laboratory. Details
of the assays that were used to identify patients with TRK fusion–positive cancer are
provided in the Supplementary Appendix.
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The primary end point for the combined analysis was the overall response rate, as assessed
by an independent radiology review committee according to the Response Evaluation
Criteria in Solid Tumors (RECIST), version 1.1.8 Secondary end points included the overall
response rate according to the investigator’s assessment, duration of response, progressionfree survival, and safety.
STUDY ASSESSMENTS
Tumor assessments were performed by means of computed tomography, magnetic resonance
imaging, and clinical measurement with electronic calipers (when appropriate), in the case
of cutaneous lesions, at baseline and every 8 weeks for 1 year and every 12 weeks thereafter
until disease progression. All tumor responses were confirmed at least 4 weeks after the
initial response. Adverse events were assessed from the date that informed consent was
obtained until at least 28 days after the last dose of larotrectinib was administered. Adverse
events were classified and graded according to the Common Terminology Criteria for
Adverse Events, version 4.0.9
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STUDY OVERSIGHT
The phase 1 study involving adults was designed by the sponsor, Loxo Oncology. The phase
1–2 study involving children was designed jointly by five of the authors and the sponsor.
The phase 2 study involving adolescents and adults was designed jointly by the first and last
authors and the sponsor. The sponsor collected and analyzed the data. The first and last
authors had access to all the data and wrote the first draft of the manuscript. All the authors
were involved in the data analysis and manuscript preparation. All the authors vouch for the
completeness and accuracy of the data and analyses and for the adherence of the studies to
N Engl J Med. Author manuscript; available in PMC 2018 August 22.
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the protocols. All the authors made the decision to submit the manuscript for publication.
Editorial support, which did not include writing, was provided by Miller Medical
Communications with funding from the sponsor.
STATISTICAL ANALYSIS
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All the analyses were conducted in accordance with the statistical analysis plan. The
decision to pool efficacy data from patients with a TRK fusion–positive tumor across all
three studies was made early in the development program on the basis of the rarity of TRK
fusions, the inherent heterogeneity of cancer types, and global regulatory advice. The
primary analysis, presented in this article, was therefore based on the first 55 patients
(children and adults) who were enrolled across the three larotrectinib studies and met the
following criteria: they had a documented TRK fusion as determined by local testing; had a
non–central nervous system primary tumor that could be assessed according to RECIST,
version 1.1; and had received one or more doses of larotrectinib. As of the data-cutoff date, a
total of 144 patients had received at least one dose of larotrectinib across the development
program.
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Analyses were performed according to the intention-to-treat principle. A true overall
response rate of at least 50% was hypothesized, and we estimated that a sample of 55
patients would provide the study with 80% power to establish a lower boundary of 30% for a
two-sided 95% exact binomial confidence interval. Ruling out a lower limit of 30% for the
overall response rate was considered to be clinically meaningful and consistent with
approved targeted therapies for genomically defined populations of patients who had
stopped having a response to previous therapies. Confidence intervals were calculated with
the use of the Clopper–Pearson method. Patients who underwent surgical resection and had
no viable tumor cells and negative margins (i.e., had a pathological complete response), as
well as having no remaining radiographic evidence of disease, were considered to have had a
complete response, consistent with RECIST, version 1.1. Duration of response and
progression-free survival were estimated by the Kaplan–Meier method according to the
investigators’ assessments of response.

RESULTS
PATIENTS
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From March 2015 through February 2017, we enrolled 55 consecutive patients across all
studies who had TRK fusion–positive cancers that could be evaluated according to RECIST,
version 1.1. The demographic characteristics of the patients, the tumor type, and fusion
characteristics are summarized in Table 1, and in Table S2 in the Supplementary Appendix.
Patients ranged in age from 4 months to 76 years.
This population of patients encompassed 17 unique cancer diagnoses, including mammary
analogue secretory carcinoma of the salivary gland (in 12 patients), infantile fibrosarcoma
(in 7), thyroid tumor (in 5), colon tumor (in 4), lung tumor (in 4), melanoma (in 4),
gastrointestinal stromal tumor (in 3), and other cancers (in 16). This distribution in the
enrollment of patients may reflect an increased vigilance of testing in rare tumor types that
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are known to be enriched for the presence of TRK fusions, such as salivary-gland cancer and
infantile fibrosarcoma.6,10,11 TRK fusions involved TRKA (NTRK1) (in 45% of the
patients), TRKB (NTRK2) (in 2%), and TRKC (NTRK3) (in 53%) and 14 unique upstream
fusion partners. These TRK fusions were prospectively identified by means of nextgeneration sequencing (in 50 patients) or fluorescence in situ hybridization (in 5) at 15
laboratories. Confirmation of expression of the fusion transcript was not required or
routinely performed.
EFFICACY

Author Manuscript

At the primary data-cutoff date of July 17, 2017, the overall response rate was 75% (95%
confidence interval [CI], 61 to 85), as determined by the independent radiology review
committee (Table 2). A total of 13% of the patients (7 patients) had a complete response,
62% (34) had a partial response, 13% (7) had stable disease, 9% (5) had progressive disease,
and 4% (2) could not be evaluated owing to early withdrawal for clinical deterioration. All
the patients were accounted for in the analysis, including the 2 patients who could not be
evaluated, per the intention-to-treat principle.
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According to the investigator’s assessment, the overall response rate was 80% (95% CI, 67
to 90) (Table 2). Responses were observed regardless of tumor type (Fig. 1A), age of the
patient, or TRK fusion characteristics (Fig. S1 in the Supplementary Appendix). The median
time to response was 1.8 months (range, 0.9 to 6.4), a time point that was consistent with the
first protocol-mandated assessment of response at 8 weeks (Fig. 1B). Two children with
locally advanced infantile fibrosarcoma had sufficient tumor shrink-age during treatment to
allow for limb-sparing surgery that was intended to be curative. Pathological assessment
confirmed negative margins (R0 surgery), and these two patients remain progression-free
without larotrectinib treatment after 4.8 months and 6.0 months of follow-up.
The median duration of response had not been reached after a median follow-up duration of
8.3 months (range, 0.03+ to 24.9+ [plus signs indicate ongoing response at the time of data
cutoff]) (Fig. 2A). The median progression-free survival had not been reached after a median
follow-up duration of 9.9 months (range, 0.7 to 25.9+) (Fig. 2B). At 1 year, 71% of
responses were ongoing, and 55% of all patients remained progression-free. As of the datacutoff date, 86% of the patients with a response (38 of 44 patients) were continuing to
receive treatment or had undergone surgery that was intended to be curative. The patient
with the longest response was the first patient with a TRK fusion–positive tumor to be
treated; this patient was still receiving therapy at 27 months.12
ADVERSE EVENTS
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Table 3 shows the adverse events, regardless of attribution, that occurred during treatment
and that were seen in at least 15% of the patients, as well as adverse events of grade 3 or
higher that were considered by the investigators to be related to larotrectinib. Clinically
significant adverse events were uncommon, with the majority (964 of 1038 events [93%]) of
all the adverse events being of grade 1 or 2. Few adverse events of grade 3 or 4, regardless of
attribution, were observed. The most common were anemia (in 11% of the patients), an
increase in the alanine aminotransferase or aspartate aminotransferase level (in 7%), weight
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increase (in 7%), and a decrease in the neutrophil count (in 7%). No grade 4 or 5 events
were considered by the investigators to be related to treatment, and no treatment-related
grade 3 adverse events occurred in more than 5% of the patients.
Of the 55 patients, 8 (15%) had their larotrectinib dose reduced. Adverse events leading to
dose reduction included an increase in the alanine aminotransferase or aspartate
aminotransferase level (in 4 patients), dizziness (in 2), and a decrease in the absolute
neutrophil count (in 2). All these events were of grade 2 or 3. In all cases, patients whose
doses were reduced had their best response maintained at the lower dose. No patients who
had a response discontinued larotrectinib because of an adverse event.
PRIMARY AND ACQUIRED RESISTANCE
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Author Manuscript

Given the high overall response rate, we sought to determine the potential mechanisms of
primary resistance to larotrectinib, defined as a best response of progressive disease, which
was observed in six patients (11%). One patient had previously been treated with another
TRK inhibitor, and tumor sequencing before the administration of larotrectinib revealed an
NTRK3 G623R mutation in the ATP-binding site of the kinase domain.13 The NTRK3
G623R mutation and its NTRK1 G595R paralogue are termed “solvent front” mutations
because they alter a hydrophilic solvent–exposed portion of the nucleotide-binding loop of
the kinase domain, sterically interfere with larotrectinib binding, and reduce the inhibitory
potency of larotrectinib.14 Tumor-derivative material was available for three of the five
remaining patients for central analysis. In all three patients, central pan-TRK
immunohistochemical testing did not confirm the presence of an expressed TRK fusion,
which raises the possibility that the test performed at the local laboratory was a false positive
or that the molecularly identified fusion was not expressed at the protein level; this finding
potentially explains the lack of response in these patients (see the Supplementary Appendix).
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We also sought to determine mechanisms of acquired resistance to larotrectinib, defined as
disease progression during treatment after a documented objective response or stable disease
for at least 6 months,15 as observed in 10 patients. Kinase domain mutations affecting the
NTRK gene involved in the fusion were identified in tumor or plasma samples that were
obtained after progression from all 9 patients who underwent repeat testing (Table S3 in the
Supplementary Appendix). Kinase domain mutations that were observed at progression
included substitutions in the solvent front position (NTRK1 G595R or NTRK3 G623R; in 7
patients), the gatekeeper position (NTRK1 F589L; in 2), and the xDFG position (NTRK1
G667S or NTRK3 G696A; in 2). The xDFG mutations occur within a portion of the kinaseactivation loop and sterically interfere with binding of the drug. All three categories of these
mutations are paralogous to acquired resistance mutations that have been described for other
classes of kinase inhibitors in oncogene-activated tumors.16,17 In 3 patients, more than one
acquired resistance mutation was identified. Among the 10 patients in whom acquired
resistance developed, 8 (80%) continued treatment with larotrectinib beyond progression
because of ongoing clinical benefit, according to the judgment of their treating physicians.
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DISCUSSION
In this series of studies, larotrectinib, a highly selective TRK inhibitor, had rapid, potent, and
durable antitumor activity in children and adults with solid tumors with TRK fusions. The
efficacy of larotrectinib in this diverse population compares favorably with response rates
that have been seen in more clinically homogenous populations of patients receiving targeted
therapy in the context of a validated oncogene. Our data not only validate TRK fusions as
therapeutic targets but also show that they lead to tumor-agnostic sensitivity to larotrectinib.
In contrast, for previously validated oncogenic drivers, drug responsiveness has been
generally contingent on the presence of a genomic aberrancy and on tumor type.18
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Larotrectinib-related adverse events that led to dose reductions were rare, and in this sample
of 55 patients with TRK fusion–positive cancer, no patients discontinued owing to drugrelated adverse events. Additional data reflecting a longer follow-up and a larger patient
experience may provide further insight into the safety profile of this agent. Similarly,
although clinically meaningful durability of response was observed, continued follow-up
will provide more information regarding the durability of larotrectinib benefit.
By sequencing tumor and plasma samples that were obtained at progression, we identified a
convergent on-target mechanism of acquired drug resistance. Mutations altering the kinase
domain of TRK explain most of the progression events that we observed. This finding is of
immediate therapeutic relevance, given the early evidence of clinical activity that has been
described with the next-generation TRK inhibitor LOXO-195.14 Specifically designed to
address acquired kinase domain mutations such as solvent front substitutions, LOXO-195 is
currently being evaluated in a phase 1–2 study involving children and adults
(ClinicalTrials.gov number, NCT03215511).
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In conclusion, TRK fusions defined a unique molecular subgroup of advanced solid tumors
in children and adults in whom larotrectinib was highly active. Durable responses were
observed without regard to the age of the patient, tumor tissue, and fusion status. The sideeffect profile of larotrectinib suggests that long-term administration is feasible for patients.
Screening strategies that include assays with the ability to detect TRK fusions will be
needed in order to identify patients who may benefit from larotrectinib.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Efficacy
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Panel A shows a waterfall plot of the maximum change in tumor size, according to tumor
type. One patient (asterisk) had a tropomyosin receptor kinase (TRK) solvent front
resistance mutation (NTRK3 G623R) at baseline owing to previous therapy. One patient
(dagger) had a pathological complete response. Data for 1 patient are not shown; the patient
had clinical deterioration and no tumor measurements after baseline were recorded. GIST
denotes gastrointestinal stromal tumor, and IFS infantile fibrosarcoma. Panel B shows a
swimmer plot of outcomes in all 55 patients. One patient (double dagger) had a missing
restaging scan after the confirmed response was established, and progression-free survival
was censored at 3.7 months.
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Figure 2. Kaplan–Meier Plots of Duration of Response among 44 Patients with a Response and
Progression-free Survival among All 55 Patients

At 6 months, 83% of the responses were ongoing, and at 1 year, 71% of the responses were
ongoing (Panel A). Tick marks indicate censored data. At 6 months, 73% of the patients
were progression-free, and at 1 year, 55% of the patients remained progression-free (Panel
B).
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Demographic and Clinical Characteristics of the 55 Patients.*
Characteristic

Value

Age
Median (range) — yr

45.0 (0.3–76.0)

Distribution — no. (%)
<2 yr

6 (11)

2–5 yr

5 (9)

6–14 yr

1 (2)

15–39 yr

12 (22)

≥40 yr

31 (56)

Sex — no. (%)

Author Manuscript

Male

29 (53)

Female

26 (47)

ECOG performance-status score — no. (%)†
0

24 (44)

1

27 (49)

2

4 (7)

No. of previous systemic chemotherapies — no. (%)
0 or 1

27 (49)

2

9 (16)

≥3

19 (35)

Tumor type — no. (%)

Author Manuscript
Author Manuscript

Salivary-gland tumor

12 (22)

Other soft-tissue sarcoma‡

11 (20)

Infantile fibrosarcoma

7 (13)

Thyroid tumor

5 (9)

Colon tumor

4 (7)

Lung tumor

4 (7)

Melanoma

4 (7)

GIST

3 (5)

Cholangiocarcinoma

2 (4)

Appendix tumor

1 (2)

Breast tumor

1 (2)

Pancreatic tumor

1 (2)

CNS metastases — no. (%)
No

54 (98)

Yes

1 (2)

TRK gene — no. (%)
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Value
25 (45)
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NTRK2

1 (2)

NTRK3

29 (53)

*

CNS denotes central nervous system, GIST gastrointestinal stromal tumor, and TRK tropomyosin receptor kinase.

†

Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability.

‡

Subtypes of other soft-tissue sarcomas included myopericytoma (in two patients), sarcoma that was not otherwise specified (in two), peripheralnerve sheath tumor (in two), spindle-cell tumor (in three), infantile myofibromatosis (in one), and inflammatory myofibroblastic tumor of the
kidney (in one).
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Overall Response Rate, According to Investigator and Central Assessment.*
Response

Investigator Assessment
(N = 55)

Central Assessment
(N = 55)

percent
Overall response rate (95% CI)†

80 (67–90)

75 (61–85)

Partial response

64‡

62

Complete response

16

13

9

13

11

9

0

4

Best response

Stable disease
Progressive disease
Could not be evaluated

Author Manuscript

*

Percentages may not total 100 because of rounding.

†

The best overall response was derived from the responses as assessed at specified time points according to the Response Evaluation Criteria in
Solid Tumors, version 1.1.

‡

Data include one patient who had a partial response that was pending confirmation at the time of the database lock. The response was
subsequently confirmed, and the patient’s treatment and response are ongoing.

Author Manuscript
Author Manuscript
N Engl J Med. Author manuscript; available in PMC 2018 August 22.

Author Manuscript

N Engl J Med. Author manuscript; available in PMC 2018 August 22.

20
24
25
22
9
15
24
22
11
9
13
11
15
5
0

Fatigue

Vomiting

Dizziness

Nausea

Anemia

Diarrhea

Constipation

Cough

Increased body weight

Dyspnea

Headache

Pyrexia

Arthralgia

Back pain

Decreased neutrophil count

7

9

0

2

4

9

5

4

4

13

9

7

4

9

15

4

Grade 2

7

0

0

2

0

0

7

0

0

2

11

2

2

0

2

7

Grade 3

Any Grade

0

0

0

2

0

0

0

0

0

0

0

0

0

0

0

0

15

15

15

16

16

18

24

25

27

29

29

31

31

33

36

42

2

0

0

0

0

0

0

0

0

0

2

2

2

0

0

5

Grade 3

percent of patients with event

Grade 4

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Grade 4

9

0

2

0

2

2

11

2

16

5

9

16

25

11

16

38

Any Grade

Treatment-Related Adverse Events

The adverse events listed here are those that occurred in at least 15% of the patients, regardless of attribution. The relatedness of the treatment to adverse events was determined by the investigators. ALT
denotes alanine aminotransferase, and AST aspartate aminotransferase.

*

31

Increased ALT or AST level

Grade 1

Adverse Events, Regardless of Attribution
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Adverse Event
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Adverse Events.*
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